{
  "symbol": "REGN",
  "year": 2025,
  "period": "Q1",
  "curated_text": "Symbol: REGN. Year: 2025. Period: Q1. ReportType: Q10. Section: Competition and Market Position. This section discusses competitors, market dynamics, and regulatory landscape.  Competitors mentioned: New Indications, Dupixent, Regeneron, Bayer, Change Research, Lynozyfic (linvoseltamab, 19.2 Dupixent, Libtayo, 41 Table of Contents Research, FDA. Context excerpt: competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part II, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our products and product candidates is subject to significant competition - Marketed Products.\" In addition, if independent not-for-profit patient assistance funds that provide copay assistance are unable to support eligible patients, this will likely have a continued negative impact on patient affordability resulting in lower utilization of higher-cost anti-VEGF agents. Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended June 30, Six Months Ended June 30, (In millions) 2025 2024 202",
  "competition_summary": [
    {
      "competitor": "New Indications",
      "mentions": 1,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part II, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pr"
    },
    {
      "competitor": "Dupixent",
      "mentions": 6,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part II, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pr"
    },
    {
      "competitor": "Regeneron",
      "mentions": 11,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part II, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pr"
    },
    {
      "competitor": "Bayer",
      "mentions": 2,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part II, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pr"
    },
    {
      "competitor": "Change Research",
      "mentions": 1,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part II, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pr"
    },
    {
      "competitor": "Lynozyfic (linvoseltamab",
      "mentions": 1,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part II, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pr"
    },
    {
      "competitor": "19.2 Dupixent",
      "mentions": 1,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part II, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pr"
    },
    {
      "competitor": "Libtayo",
      "mentions": 1,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part II, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pr"
    },
    {
      "competitor": "41 Table of Contents Research",
      "mentions": 1,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part II, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pr"
    },
    {
      "competitor": "FDA",
      "mentions": 1,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part II, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pr"
    }
  ]
}